AML1-ETO Antibody - ChIP-seq Grade (sample size)

Catalog Number
20 µl
  Bulk order
Other format

Alternative name: RUNX1-RUNX1T1

Polyclonal antibody raised in rabbit against the AML1-ETO fusion protein using a KLH-conjugated synthetic peptide.

Concentrationnot determined
Species reactivityHuman
PurityWhole antiserum
PrecautionsThis product is for research use only. Not for use in diagnostic or therapeutic procedures.
Applications Suggested dilution References
ChIP/ChIP-seq * 4 μl/ChIP Fig 1, 2
ELISA 1:500 Fig 3
Western Blotting 1:1,000 Fig 4

* Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 μl per IP.

  • Validation data

    AML1-ETO Antibody ChIP Grade

    Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO
    ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.

    A.ChIP-seq signals on chromosome 3
    AML1-ETO Antibody ChIP-seq Grade
    B.Genomic region on chromosome 3 surrounding the OGG1 gene
    AML1-ETO Antibody for ChIP-seq
    C. Genomic region on chromosome 9 surrounding the FUT7 gene
    AML1-ETO Antibody for ChIP-seq assay
    D. Genomic region on chromosome 12 surrounding the NFE2 gene
    AML1-ETO Antibody validated in ChIP-seq

    Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO
    ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.

    AML1-ETO Antibody ELISA Validation

    Figure 3. Determination of the antibody titer
    To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.

    AML1-ETO Antibody validated in  Western Blot

    Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO
    Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.

  • Target Description

    This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.

  •  実験手法
    Western blot : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies. Learn more about: Load... Read more
    Enzyme-linked immunosorbent assay. Read more
    ChIP-seq (ab)
    Read more
    ChIP-qPCR (ab)
    Read more
  •  資料
    Antibodies you can trust POSTER
    Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of lar...
    Epigenetic Antibodies Brochure BROCHURE
    More than in any other immuoprecipitation assays, quality antibodies are critical tools in many e...
    Datasheet AML1-ETO C15310197 DATASHEET
    Datasheet description
  •  Safety sheets
    AML1-ETO antibody SDS GB en Download
    AML1-ETO antibody SDS US en Download
    AML1-ETO antibody SDS BE nl Download
    AML1-ETO antibody SDS BE fr Download
    AML1-ETO antibody SDS FR fr Download
    AML1-ETO antibody SDS ES es Download
    AML1-ETO antibody SDS DE de Download
    AML1-ETO antibody SDS JP ja Download
  •  出版物

    How to properly cite this product in your work

    Diagenode strongly recommends using this: AML1-ETO Antibody - ChIP-seq Grade (sample size) (Diagenode Cat# C15310197-20 Lot# A706-002). Click here to copy to clipboard.

    Using our products in your publication? Let us know!

    RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
    Ptasinska A, Pickin A, Assi SA, Chin PS, Ames L, Avellino R, Gröschel S, Delwel R, Cockerill PN, Osborne CS, Bonifer C
    Acute myeloid leukemia (AML) is associated with mutations in transcriptional and epigenetic regulator genes impairing myeloid differentiation. The t(8;21)(q22;q22) translocation generates the RUNX1-ETO fusion protein, which interferes with the hematopoietic master regulator RUNX1. We previously showed that the maint...

    Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization
    Schanda J. et al.
    RUNX1/ETO, the product of the t(8;21) chromosomal translocation, is required for the onset and maintenance of one of the most common forms of acute myeloid leukemia (AML). RUNX1/ETO has a modular structure and, besides the DN A-binding domain (Runt), contains four evolutionary conserved functional domains named nerv...

    The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs
    Mandoli A. et al.
    The t(8;21) acute myeloid leukemia (AML)-associated oncoprotein AML1-ETO disrupts normal hematopoietic differentiation. Here, we have investigated its effects on the transcriptome and epigenome in t(8,21) patient cells. AML1-ETO binding was found at promoter regions of active genes with high levels of histone acetyl...

    MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML
    Vegi NM et al.
    Homeobox genes are known to be key factors in leukemogenesis. Although the TALE family homeodomain factor Meis1 has been linked to malignancy, a role for MEIS2 is less clear. Here, we demonstrate that MEIS2 is expressed at high levels in patients with AML1-ETO-positive acute myeloid leukemia and that growth of AML1-...

    Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis
    Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K
    DNA methylation is tightly regulated throughout mammalian development, and altered DNA methylation patterns are a general hallmark of cancer. The methylcytosine dioxygenase TET2 is frequently mutated in hematological disorders, including acute myeloid leukemia (AML), and has been suggested to protect CG dinucleotide...

    Immune evasion by oncogenic proteins of acute myeloid leukemia.
    Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, Mandelboim O
    PML-RARA and AML1-ETO are important oncogenic fusion proteins that play a central role in transformation to acute myeloid leukemia (AML). Whether these fusion proteins render the tumor cells with immune evasion properties is unknown. Here we show that both oncogenic proteins specifically downregulate the expression ...

    ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.
    Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG
    ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs ...


  • FASEB Biological Methylation: Fundamental Mechanisms
    Porto, Portugal
    Jul 28-Aug 1, 2024


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy